决策合作伙伴的开发和评估:为艾滋病毒缓解提供决策援助 临床试验参与
Rebecca R Moultrie1, Gail Henderson2, Sarah Nelson Potter3
1Center for Communication and Engagement Research, Center for Communication Science, RTI International, 3040 E. Cornwallis Road, P.O. Box 12194, 27709, Research Triangle Park, NC, USA. rmoultrie@rti.org.
AIDS and behavior
|June 10, 2025
概括
决策有助于提高对HIV缓解临床试验的理解. 决策合作伙伴工具显著减少了决策冲突,并增加了参与者之间的知识,帮助知情同意.
科学领域:
- 临床试验 临床试验
- 在知情同意的情况下同意.
- 健康决策的制定方法
背景情况:
- 艾滋病毒缓解临床试验需要参与者对风险,益处和程序做出明智的决定.
- 决策辅助工具 (DA) 是旨在支持个人做出明智选择的工具,以做出偏好敏感的决策.
研究的目的:
- 开发和评估一种名为"决策合作伙伴"的新型决策辅助工具,专门用于加强艾滋病毒缓解临床试验中的知情同意.
- 评估决策合作伙伴对艾滋病毒感染者 (PLWHIV) 之间的决策冲突和知识的有用性和影响.
主要方法:
- 在开发和测试决策合作伙伴时,采用了一种代的混合方法方法.
- 开发涉及广泛的研究和参与PLWHIV,倡导者,研究人员,试验者和临床医生.
- 评估包括评估20个PLWHIV的有用性,减少决策冲突和知识增加.
主要成果:
- 90%的PLWHIV发现决策伙伴对决策有用.
- 在使用决策合作伙伴后,观察到决策冲突的统计显著下降 (37.3到16.8,p=.007).
- 从干预前到干预后,参与者的知识显著增加 (z = -3.11,p < .01).
结论:
- 决策合作伙伴在改善艾滋病毒缓解试验的知情同意过程方面表现出显著的希望.
- DA有效地减少了决策冲突并增强了知识,赋予PLWHIV参与试验决策的权力.
- 这种工具可以增强目前的知情同意程序,从而在艾滋病毒治愈研究中做出更明智的选择.
相关概念视频
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Clinical Trials
10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.2K
Therapeutic Drug Monitoring: Affecting Factors
202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202
Retrovirus Life Cycles
49.3K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.3K
Bioavailability Study Design: Healthy Subjects Versus Patients
144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144
Bioequivalence studies: Biowaivers
229
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
229


